A 型肉毒素膀胱内阻滞治疗女性膀胱过度活动症的临床效果观察

目的：探讨A 型肉毒素膀胱内阻滞治疗女性膀胱过度活动症的临床效果。方法：选择2010 年10 月至2012 年10 月,哈尔滨 医科大学附属第四医院泌尿外科收治的女性膀胱过度活动症患者24 例,随机分为治疗组和对照组,治疗组(A 组)选用国产A 型 肉毒素(衡力)100 IU 治疗,用10 mL 生理盐水稀释后,通过膀胱镜进行壁内注射;对照组(B 组)患者给予口服经典的抗胆碱制剂, 酒石酸托特罗定片,每天口服2 次,每次2 mg,疗程不少于6 周。于治疗前,治疗后1 周和4 周观察和比较两组患者的IPSS评分、 初尿意膀胱容量、最大膀胱容量。结果：与治疗前比较,A 组治疗后1 周,IPSS评分显著下降(P<0.05),初尿意膀胱容量及最大膀胱 容量显著上升(P<0.05),治疗后第2 周和第4 周均维持在相当水平,残余尿量第1 周未见明显下降(P>0.05),第4 周时与基线比较 下降明显(P<0.05);B组于治疗后第4 周时,以上三项指标与治疗前比较才有统计学差异(P<0.05),残余尿量在第1 周即有明显下 降(P<0.05),并且第4 周时仍维持第1 周水平(P>0.05)。此外,治疗后第1 周两组比较以上指标比较有统计学差异(P<0.05),而治疗 后第4 周无明显差异(P>0.05)。结论：经尿道膀胱壁内肉毒素A 注射和口服酒石酸托特罗定均是治疗女性膀胱过度活动症的有效 方法,但A 型肉毒素膀胱内注射起效更快,同时由于其接触性和直观性,疗效更确切。     

Treatment of severe neuroleptic-induced tardive torticollis

BACKGROUND: The aim of this paper is to describe a case of severe neuroleptic-induced tardive torticollis successfully treated with a combination of clozapine, clonazepam and botulinum toxin-A. CASE REPORT: The patient, a 30-year old man with a seven-year history of delusional disorder experienced severe right torticollis with painful tightness of the neck and elevation of the shoulder. At this time he was receiving haloperidol 20 mg, trifluoperazine 5 mg, zuclopenthixol 20 mg and biperidine 4 mg daily. The combination therapy with clozapine and clonazepam and the long-term use of botulinum toxin-A resulted in a complete remission of dystonic movements. CONCLUSIONS: The present observations provide evidence indicating that this combination therapy may be of benefit in patients with severe neuroleptic-induced tardive torticollis.     

A型肉毒素膀胱内阻滞治疗女性膀胱过度活动症的临床效果观察

目的：探讨A型肉毒素膀胱内阻滞治疗女性膀胱过度活动症的临床效果。方法：选择2010年10月至2012年10月,哈尔滨医科大学附属第四医院泌尿外科收治的女性膀胱过度活动症患者24例,随机分为治疗组和对照组,治疗组（A组）选用国产A型肉毒素（衡力）100IU治疗,用10mL生理盐水稀释后,通过膀胱镜进行壁内注射;对照组（B组）患者给予口服经典的抗胆碱制剂,酒石酸托特罗定片,每天口服2次,每次2mg,疗程不少于6周。于治疗前,治疗后1周和4周观察和比较两组患者的1PSS评分、初尿意膀胱容量、最大膀胱容量。结果：与治疗前比较,A组治疗后1周,IPSS评分显著下降（P〈0．05）,初尿意膀胱容量及最大膀胱容量显著上升（P〈0．05）,治疗后第2周和第4周均维持在相当水平,残余尿量第1周未见明显下降（P〉0．05）,第4周时与基线比较下降明显（P〈0．05）;B组于治疗后第4周时,以上三项指标与治疗前比较才有统计学差异（P〈0．05）,残余尿量在第1周即有明显下降（P〈0．05）,并且第4周时仍维持第1周水平（P〉0．05）。此外,治疗后第1周两组比较以上指标比较有统计学差异（P〈0．05）,而治疗后第4周无明显差异（P〉0．05）。结论：经尿道膀胱壁内肉毒素A注射和口服酒石酸托特罗定均是治疗女性膀胱过度活动症的有效方法,但A型肉毒素膀胱内注射起效更快,同时由于其接触性和直观性,疗效更确切。     

Polyclonal antibodies against NCAM reduce paralysis-induced axonal sprouting

The neural cell adhesion molecule (NCAM) is upregulated in paralyzed muscles but the functional role of this upregulation is not clear. We have investigated the possible involvement of NCAM in botulinum toxin-induced axonal sprouting in mouse soleus muscles. Starting 4 days after botulinum toxin-A injection, the paralyzed muscles were exposed daily for 6 or 10 days to either rabbit polyclonal NCAM antibody or control solutions (preimmune serum or saline) or remained without further treatment. By 10 days after botulinum toxin injection, the mean number of sprouts and the mean total length of sprouts, respectively, in zinc iodide<@150>osmium-stained preparations were 2.2 and 212 μm in untreated and control treated muscles but 1.0 and 51 μm in anti-NCAM treated muscles. By 14 days, the mean number of sprouts rose to 2.9 in untreated muscles but only 1.6 in anti-NCAM treated muscles. Macrophages/monocytes, probably originating from neighboring tissue damaged by the daily injections, were present in muscles of all groups. No T lymphocytes and no signs of muscle fiber damage were found, however, rendering antibody-mediated cytotoxic reactions as unlikely. From the blocking effects of anti-NCAM, it is concluded that NCAM plays a major role in the growth of paralysis-induced axonal sprouts.     

A型肉毒毒素联合CO2点阵激光治疗眼周皱纹的近期疗效评估

目的:探讨A型肉毒毒素联合CO_2点阵激光治疗眼周皱纹的近期临床疗效。方法:选择2013年6月到2014年6月我院接收眼部皱纹改善手术的患者90例,随机分为激光组、肉毒毒素组及联合治疗组,各30例,分别给予CO_2点阵激光治疗、A型肉毒毒素注射和A型肉毒毒素注射联合CO_2点阵激光治疗。所有患者在治疗后7 d、1月及3月进行疗效随访评价,比较三组不良反应情况。结果:三组患者眼周皱纹均有所改善,治疗1个月时效果最为明显。激光组的静态皱纹治疗效果明显,对动态皱纹治疗效果不明显;肉毒毒素组对动态皱纹治疗效果明显,对静态皱纹治疗效果不明显;联合治疗组对静态皱纹和动态皱纹均有明显的改善,其满意度评价总分数明显高于其他两组。三组患者对CO_2点阵激光和注射A型肉毒毒素所引起疼痛均能耐受,安全性好。结论:A型肉毒毒素联合CO_2点阵激光对静态皱纹和动态皱纹均有明显的改善作用,且不良反应轻,安全性好。     

Double-blind,placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines

The objective of this study was to evaluate the efficacy and safety of botulinum toxin type A for the treatment of glabellar lines. Patients with moderate or severe glabellar lines at maximal frown received intramuscular injections of placebo or 20 U of botulinum toxin type A (Botox; Allergan, Inc., Irvine, Calif.) distributed among five injection sites (one in the procerus muscle and two in each corrugator supercilii). Follow-up assessments were performed at 7, 30, 60, 90, and 120 days after injections. Efficacy measures were the physician's rating of glabellar line severity at maximal frown and at rest (none, mild, moderate, or severe) and the patient's global assessment of changes in glabellar lines, from +4 (100 percent better) to -4 (100 percent worse). A total of 273 patients were enrolled (botulinum toxin, 202 patients; placebo, 71 patients). All except five patients (botulinum toxin, two patients; placebo, three patients) completed the study. For the physician's rating at maximal frown, the responder rate (percentage of patients with severity ratings of none or mild in follow-up evaluations) for the botulinum toxin group peaked at 77 percent at day 30 and was significantly greater than that for the placebo group at every follow-up visit (p < 0.001). For the patient's assessment, the responder rate (percentage of patients with scores of +2 or more) for the botulinum toxin group peaked at 89 percent at day 30 and was significantly greater than that for the placebo group at every follow-up visit (p < 0.001). Rates of adverse events were similar for the two groups. The only adverse event with an incidence of >/=5 percent was headache (botulinum toxin, 11 percent; placebo, 20 percent). The incidence of blepharoptosis was 1 percent for the botulinum toxin group. Botulinum toxin type A was remarkably safe and effective in reducing glabellar lines.     

New indications for botulinum toxin type a in cosmetics: mouth and neck

Botulinum toxin type A is frequently used to smooth hyperkinetic lines in the periocular and forehead areas of the upper face, but it has been used less frequently for indications in the lower face and neck. This study was designed to determine whether botulinum toxin treatment of the mouth and neck areas is as clinically successful as the treatment of the upper face. This was a retrospective study of patients who were treated with botulinum toxin type A (Botox) to soften hyperkinetic facial wrinkles. Of 100 patients randomly selected from a single clinical practice, 91 met the inclusion criteria and were divided into two groups for analysis. The 56 patients in group 1 did not receive treatment in the mouth and neck areas, whereas the 35 patients in group 2 were treated at least once in the mouth and neck areas. Patients were surveyed for periods ranging from 7 to 49 months. Most patients in each group had a single botulinum procedure during this period. Both groups of patients had comparable improvement of wrinkles both at the evaluation immediately after the neuromuscular blockade and during follow-up. In comparison with patients whose treatment was confined to the upper face, patients who received global treatment with botulinum toxin type A, including injections in the mouth and neck areas, were injected in more sites per procedure and had more procedures in combination with other therapies. Patient satisfaction with botulinum toxin treatment and outcomes was high in both groups. Botulinum toxin type A is an important tool within the therapeutic spectrum for the treatment of hyperkinetic facial wrinkles, including those in the areas of the mouth and neck.     

Efficient DNA fingerprinting of Clostridium botulinum types A, B, E, and F by amplified fragment length polymorphism analysis

Amplified fragment length polymorphism (AFLP) analysis was applied to characterize 33 group I and 37 group II Clostridium botulinum strains. Four restriction enzyme and 30 primer combinations were screened to tailor the AFLP technique for optimal characterization of C. botulinum. The enzyme combination HindIII and HpyCH4IV, with primers having one selective nucleotide apiece (Hind-C and Hpy-A), was selected. AFLP clearly differentiated between C. botulinum groups I and II; group-specific clusters showed <10% similarity between proteolytic and nonproteolytic C. botulinum strains. In addition, group-specific fragments were detected in both groups. All strains studied were typeable by AFLP, and a total of 42 AFLP types were identified. Extensive diversity was observed among strains of C. botulinum type E, whereas group I had lower genetic biodiversity. These results indicate that AFLP is a fast, highly discriminating, and reproducible DNA fingerprinting method with excellent typeability, which, in addition to its suitability for typing at strain level, can be used for C. botulinum group identification.     

Comparative diagnostic accuracy of knee adduction moments in knee osteoarthritis: a case for not normalizing to body size

Previous authors have questioned the practice of normalizing the external knee adduction moment during gait to body size when investigating dynamic joint loading in knee osteoarthritis (OA). The purpose of this study was to compare the abilities of non-normalized and normalized external knee adduction moments during gait in discriminating between patients with least and greatest severity of radiographic medial compartment knee OA. Subjects with mild (n=118) and severe (n=115) medial compartment knee OA underwent three-dimensional gait analysis. The peak external knee adduction moment was calculated and kept in its original units (Nm), normalized to body mass (Nm/kg) and normalized to body weight and height (%BW × Ht). Receiver Operating Characteristic (ROC) curve analysis indicated that non-normalized values better discriminated between patients with mild and severe knee OA. The area under the ROC curve for non-normalized peak knee adduction moments (0.63) was significantly (p<0.05) greater than when normalized to body mass (0.58), or to body weight times height (0.57). Post-hoc analysis of covariance indicated the mean difference in peak knee adduction moment between OA severity groups (7.23 Nm, p=0.003) was reduced by approximately 50% (3.60 Nm, p=0.09) when adjusted for mass. These findings are consistent with the suggestion that non-normalized values are more sensitive to radiographic disease progression. We suggest including knee adduction moment values that are not normalized to body size when investigating knee OA.     

Temporal brow lift using botulinum toxin A

The objective of this study was to determine whether brow elevation occurs as a result of paralysis of brow depressors after botulinum toxin A injection. The study's design was a prospective case series with pretreatment and posttreatment outcome evaluation with statistical analysis at a university-based division of facial plastic surgery private clinic. Twenty-two patients of a consecutive sample desiring a cosmetic enhancement underwent injection of botulinum toxin A directed to brow depressors. Injections consisted of 7 to 10 units of botulinum toxin A (Botox, Allergan, Irvine, Calif.) into selected brow depressor muscle (lateral orbicularis oculi) bilaterally. No patients withdrew for adverse effects. All patients were evaluated 2 weeks after treatment. The outcomes were measured by change in brow elevation along vertical axis extending from both midpupil and lateral canthus to the caudal row of brow hairs with eyes at neutral gaze and the head at Frankfort plane. Preintervention and postintervention brow height was measured by the primary clinical investigator. The average brow elevation from the midpupil observed after selected injection of brow depressors with botulinum toxin A was 1.02 mm (p = 0.038). The average brow elevation from the lateral canthus observed after selected injection of brow depressors with botulinum toxin A was 4.83 mm (p<0.0001). Significant temporal brow elevation occurs as the result of paralysis of brow depressors by using botulinum toxin A injection. This procedure may be considered an alternative to surgical brow elevation.     

Effect of a single botulinum toxin injection on bone development in growing rabbits

Intramuscular injections with botulinum toxin A (BTX-A) lead to a rapid decrease in muscle mass and force, but the effect of this drug on bone development is unclear. In the present pilot study we evaluated the effect of a one-time injection of BTXA in growing rabbits. Twelve young (weight 1.5 kg) New Zealand rabbits were randomly assigned to receive either BTX-A (total dose 8 units per kg body weight) or sodium chloride 0.9% injections into the left quadriceps and gastrocnemius muscles. Both groups continued to gain weight in a similar manner following the injection. However, when the animals were sacrificed at five weeks after the injection, the group receiving BTX-A had a significant deficit (of 10%) in gastrocnemius muscle mass on the injected side, whereas no significant side-difference was found for the quadriceps. BTX-A injections did not affect the length of the tibia. Nevertheless, bone mineral content of the whole tibia, as measured by dual-energy X-ray absorptiometry, was 7% lower in the BTX-A injected side than on the contralateral side. Peripheral quantitative computed tomography showed that this bone mass deficit was larger in the metaphysis than in the epiphysis or diaphysis. In the diaphysis, the bone mass deficit was due to a reduction in cross-sectional bone dimensions, which equally affected the cross-section of the entire bone, the cortical compartment and the marrow space. BTX-A injections did not have a detectable effect on cortical bone mineral density. The bone mass deficit in the diaphysis thus appeared to be caused by a lack of periosteal bone apposition rather than increased endocortical or intracortical resorption. These preliminary data suggest that intramuscular BTX-A injections can have a deleterious effect on the development of bones that are loaded by the injected muscles.     

Apolipoprotein A-IV stimulates duodenal vagal afferent activity to inhibit gastric motility via a CCK1 pathway

Apolipoprotein A-IV (apo A-IV), a peptide expressed by enterocytes in the mammalian small intestine and released in response to long-chain triglyceride absorption, may be involved in the regulation of gastric acid secretion and gastric motility. The specific aim of the present study was to determine the pathway involved in mediating inhibition of gastric motility produced by apo A-IV. Gastric motility was measured manometrically in response to injections of either recombinant purified apo A-IV (200 microg) or apo A-I, the structurally similar intestinal apolipoprotein not regulated by triglyceride absorption, close to the upper gastrointestinal tract in urethane-anesthetized rats. Injection of apo A-IV significantly inhibited gastric motility compared with apo A-I or vehicle injections. The response to exogenous apo A-IV injections was significantly reduced by 77 and 55%, respectively, in rats treated with the CCK(1) receptor blocker devazepide or after functional vagal deafferentation by perineural capsaicin treatment. In electrophysiological experiments, isolated proximal duodenal vagal afferent fibers were recorded in vitro in response to close-arterial injection of vehicle, apo A-IV (200 microg), or CCK (10 pmol). Apo A-IV stimulated the discharge of duodenal vagal afferent fibers, significantly increasing the discharge in 4/7 CCK-responsive units, and the response was abolished by CCK(1) receptor blockade with devazepide. These data suggest that apo A-IV released from the intestinal mucosa during lipid absorption stimulates the release of endogenous CCK that activates CCK(1) receptors on vagal afferent nerve terminals initiating feedback inhibition of gastric motility.     

Experimentally reduced hip abductor function during walking: Implications for knee joint loads

Hip and knee functions are intimately connected and reduced hip abductor function might play a role in development of knee osteoarthritis (OA) by increasing the external knee adduction moment during walking. The purpose of this study was to test the hypothesis that reduced function of the gluteus medius (GM) muscle would lead to increased external knee adduction moment during level walking in healthy subjects. Reduced GM muscle function was induced experimentally, by means of intramuscular injections of hypertonic saline that produced an intense short-term muscle pain and reduced muscle function. Isotonic saline injections were used as non-painful control. Fifteen healthy subjects performed walking trials at their self-selected walking speed before and immediately after injections, and again after 20 min of rest, to ensure pain recovery. Standard gait analyses were used to calculate three-dimensional trunk and lower extremity joint kinematics and kinetics. Surface electromyography (EMG) of the glutei, quadriceps, and hamstring muscles were also measured. The peak GM EMG activity had temporal concurrence with peaks in frontal plane moments at both hip and knee joints. The EMG activity in the GM muscle was significantly reduced by pain (?39.6%). All other muscles were unaffected. Peaks in the frontal plane hip and knee joint moments were significantly reduced during pain (?6.4% and ?4.2%, respectively). Lateral trunk lean angles and midstance hip joint adduction and knee joint extension angles were reduced by ?1°. Thus, the gait changes were primarily caused by reduced GM function. Walking with impaired GM muscle function due to pain significantly reduced the external knee adduction moment. This study challenge the notion that reduced GM function due to pain would lead to increased loads at the knee joint during level walking.     

Bulky DNA adducts in human sperm: relationship with fertility,semen quality,smoking, and environmental factors

The integrity of DNA of spermatogenic cells can be affected by endogenous and exogenous genotoxic factors. Resulting DNA damage in spermatozoa may significantly contribute to impaired fertility. Here, the 32P-postlabeling method was used to analyze the levels of bulky DNA adducts in sperm cells in a group of 179 males, either healthy donors or patients with an impaired fertility. When all donors were analyzed, the levels of bulky DNA adducts was 1.2-fold higher in smokers than in non-smokers, but the difference was not statistically significant (P=0.054). However, a statistically significant difference existed between current smokers and never smokers among the healthy individuals (1.7-fold increase, P=0.008). No correlation between alcohol or coffee consumption and sperm DNA adducts was found. The levels of DNA adducts in sperm seemed to be unaffected by environmental and occupational factors. On the other hand, groups of healthy persons and patients with male-factor infertility differed significantly with respect to the level of bulky DNA adducts (P=0.012). A significant negative correlation between DNA adducts and sperm concentration or sperm motility existed among patients with an impaired fertility (n=93; P<0.029, r(S)=-0.225). These results suggest that DNA adducts in sperm cells can be applied as potential biomarkers in studies of human infertility.     

Increased hip adduction during running is associated with patellofemoral pain and differs between males and females: A case-control study

Patellofemoral pain is common amongst recreational runners and associated with altered running kinematics. However, it is currently unclear how sex may influence kinematic differences previously reported in runners with patellofemoral pain. This case-control study aimed to evaluate lower limb kinematics in males and females with and without patellofemoral pain during running. Lower limb 3D kinematics were assessed in 20 runners with patellofemoral pain (11 females, 9 males) and 20 asymptomatic runners (11 females, 9 males) during a 3 km treadmill run. Variables of interest included peak hip adduction, internal rotation and flexion angles; and peak knee flexion angle, given their previously reported association with patellofemoral pain. Age, height, mass, weekly run distance and step rate were not significantly different between groups. Mixed-sex runners with patellofemoral pain were found to run with a significantly greater peak hip adduction angle (mean difference = 4.9°, d = 0.91, 95% CI 1.4–8.2, p = 0.01) when compared to matched controls, but analyses for all other kinematic variables were non-significant. Females with patellofemoral pain ran with a significantly greater peak hip adduction angle compared to female controls (mean difference = 6.6°, p = 0.02, F = 3.41, 95% CI 0.4–12.8). Analyses for all other kinematic variables between groups (males and females with/without PFP) were non-significant. Differences in peak hip adduction between those with and without patellofemoral pain during running appear to be driven by females. This potentially highlights different kinematic treatment targets between males and females. Future research is encouraged to report lower limb kinematic variables in runners with patellofemoral pain separately for males and females.     

Peroral Endoscopic Myotomy Can Improve Esophageal Motility in Patients with Achalasia from a Large Sample Self-Control Research (66 Patients)

Background

Peroral endoscopic myotomy (POEM) as a new approach to achalasia attracts broad attention. The primary objective of this study was to evaluate the results with esophageal motility after POEM through the first large sample clinical research.

Patients and Methods

We have a self-control research with all patients (205 in total) who underwent POEM from 2010 to 2014 at our Digestive Endoscopic Center, 66 patients of which underwent high resolution manometry (HRM) before and after POEM in our motility laboratory. Follow-ups last for 5.6 months on average. Outcome variables analyzed included upper esophageal sphincter pressure (UESP), upper esophageal sphincter residual pressure (UESRP), lower esophageal sphincter pressure (LESP), lower esophageal sphincter residual pressure (LESRP) and esophageal body peristalsis. We have a statistical analysis to illustrate how POEM impacts on the change of esophageal motility.

Results

The symptoms related to dysphagia were relieved in 95% of patients in recent term after POEM. While HRM showed a statistically significant reduction of URSRP, LESP and LESRP (P<0.01), however, peristalsis was not consistently affected. There were 11 patients who had undergone other prior endoscopic treatment (endoscopic dilation or botulinum toxin injection) and 55 patients had not. The statistical difference (P>0.05) did not occur for these two groups on LESP and LESRP reduction.

Conclusions

POEM clearly relieved the symptoms related to dysphagia by lowering the pressure of upper esophageal sphincter (UES) and lower esophageal sphincter (LES),and other endoscopic treatment before POEM did not affect the improvement of LES pressure. These results are concluded from our short-term follow-up study, while the long-term efficacy remains to be further illustrated.

Trial Registration

Chinese Clinical Trial Register ChiCTR-TRC-12002204)     

EEG Reflection of Clinical Effects Dynamics during Botulinum Toxin Therapy of Movement Disorders under Long-Term Consciousness Disorders

When studying the dynamics of brain electric activity (BEA) in the course of botulinum toxin (Incobotulinumtoxin A) injections into all hypertonic muscles of 16 patients suffering from post-coma longterm consciousness disorders, BEA changes were observed to start within the first minutes after the first intramuscular injection of botulinum toxin, while not being associated with any pain stimulus response. Despite the diversity of brain lesions in these patients, the dynamics of BEA reorganisation during botulinum toxin therapy showed the presence of pathological sensorimotor integration involving the whole brain in case of long-term consciousness disorders. In our opinion, it is expressed in a pathological state developing in the brain, which affects the polyfunctional capabilities of neurons. This state is unbalanced due to destabilizing effect at the beginning of the reduction by pathological hyperafferentation from muscles and, in principle, can be disrupted at a complete reduction. It is, however, maintained by memory matrix, which manifests itself in the shape of oscillation process during its disruption when the newly build-up BEA is occasionally displaced by the previous one. During the reduction of sensory hyperafferentation, BEA reorganisation initially involved the motor cortex (in 15 out of 16 patients) and then spread to other brain areas, including those responsible for the higher mental functions, vision, and hearing. The first transiently decreased muscle tone (in all patients) and improvement of neurological signs of awareness (in some patients) were observed immediately after injecting all hypertonic muscles with widespread BEA changes. The appearance of high-frequency EEG activity in the frontal areas was considered as a universal marker of an improved functional state of the brain during the disruption of pathological sensorimotor integration even before clinical signs, suggesting neuronal readiness to maintain various activities. In view of data obtained, the first-stage clinical measures in patients with disorders of consciousness should focus on disrupting pathological sensorimotor integration, opening a way for restoring neuronal functional activity, provided that all “pathological afferents” are reduced.     

Agar Concentration in Counting Clostridium Colonies

Decreasing the agar concentration of a counting medium from the usual 1.5% resulted in larger colonies with less interference from gas in Clostridium botulinum 115B and C. sporogenes PA 3679. Optimal agar concentration was 0.65% for C. botulinum with 24-hr incubation and 0.50% for C. sporogenes with 48-hr incubation. Lower concentrations yielded growth too diffuse for counting. Motility was considered the explanation for increased colony size in softer agar. The greater the degree of motility, the greater would be the diffusibility expected, and thus the higher the agar concentration required to insure discrete colonies. For quantitating motility, evaluations were made by use of microscopic examination of liquid cultures and rate of diffusion in a semisolid medium. With both criteria, the degree of motility of C. botulinum 115B clearly exceeded that of C. sporogenes PA 3679. Small-colony variants of C. botulinum in 0.65% agar yielded only small colonies on subculture, with a corresponding decrease in degree of motility of the cells by both criteria. Colony size of the nonmotile C. perfringens ATCC 3624 was unaffected by lowered agar concentrations.     

Gait in rheumatoid arthritis: an electrogoniometric investigation

For the purpose of detecting early aberrations of gait in rheumatoid arthritis 17 women suffering from that disease were examined. They were all under 50 years of age and had an essentially normal range of motility in the hips, knees and ankles. Eleven healthy women walking at voluntary speed and 6 healthy women walking at the same slow speed as the RA patients were included as controls. The recordings were made while the subject walked on a treadmill with a computerized electrogoniometer measuring the angular excursions of the hip, knee and ankle in three planes simultaneously. The patients with RA walked at a slower speed than did the healthy subjects (0.6 vs 1.2 ms-1). The angular excursions, i.e. inward and outward rotation, abduction and adduction, flexion and extension, were significantly less in the RA patients than in the healthy subjects who walked at voluntary speed. As compared to the healthy subjects walking at a slow speed, the differences in range of motility were much smaller. The major aberrations of the gait pattern were found in the ankles and feet, which showed reduced internal rotation (7 vs 10 degrees), adduction (6 vs 12 degrees) and a less pronounced plantar flexion at toe off (1 vs 8 degrees).     

Botulinum toxin injections as a method for chemically denervating skeletal muscle to test functional hypotheses: a pilot study in Lepomis cyanellus

In this study, we demonstrate that botulinum toxin can be used to chemically denervate muscles to test functional hypotheses. We injected research-grade type A botulinum toxin complex into pectoral fin abductors (abductor superficialis) of green sunfish (Lepomis cyanellus) to determine whether chemical denervation would eliminate the ability of a particular muscle to contribute to overall pectoral fin movements. Reduction of target muscle activity occurred within 8 d of the injection, and paralysis was confirmed using electromyography. No paralysis was seen in the adjacent muscles (abductor profundus) or in positive controls (saline injections). Paralysis occurred more slowly and at lower doses than previously documented for mammals. However, botulinum toxin complex (500 kDa) was used here, whereas previous studies have used purified toxin (150 kDa). Therefore, differences in physiological responses between fish and mammals cannot yet be distinguished from differences caused by the toxin type. However, we note that the toxin complex is less likely to diffuse across muscle fascia (because it is large), which should minimize paralytic effects on adjacent muscles. We suggest that botulinum toxin holds great promise as a chemical denervation agent in functional studies of animal locomotion and feeding behaviors.